

1 ***Multi-organ genetic causal connections inferred from imaging and clinical data through***  
2 ***Mendelian randomization***

3

4 **Running title: MR atlas for multi-organ images**

5

6 Juan Shu<sup>1</sup>, Rong Zheng<sup>2</sup>, Carlos Copana<sup>1</sup>, Bingxuan Li<sup>3</sup>, Zirui Fan<sup>1,4</sup>, Xiaochen Yang<sup>1</sup>, Yilin Yang<sup>5</sup>,  
7 Xiyao Wang<sup>3</sup>, Yujue Li<sup>1</sup>, Bowei Xi<sup>1</sup>, Tengfei Li<sup>6,7</sup>, Hongtu Zhu<sup>8,9,10,11\*</sup>, and Bingxin Zhao<sup>1,4\*</sup>

8

9 <sup>1</sup>Department of Statistics, Purdue University, West Lafayette, IN 47907, USA.

10 <sup>2</sup>Department of Ultrasound Imaging, First Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001,  
11 China.

12 <sup>3</sup>Department of Computer Science, Purdue University, West Lafayette, IN 47907, USA.

13 <sup>4</sup>Department of Statistics and Data Science, University of Pennsylvania, Philadelphia, PA 19104, USA.

14 <sup>5</sup>Department of Computer and Information Science and Electrical and Systems Engineering, School of  
15 Engineering & Applied Science, University of Pennsylvania, Philadelphia, PA 19104, USA.

16 <sup>6</sup>Department of Radiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

17 <sup>7</sup>Biomedical Research Imaging Center, School of Medicine, University of North Carolina at Chapel Hill,  
18 Chapel Hill, NC 27599, USA.

19 <sup>8</sup>Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

20 <sup>9</sup>Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

21 <sup>10</sup>Department of Computer Science, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

22 <sup>11</sup>Department of Statistics and Operations Research, University of North Carolina at Chapel Hill, Chapel Hill,  
23 NC 27599, USA.

24

25 *\*Corresponding authors:*

26 Hongtu Zhu

27 3105C McGavran-Greenberg Hall, 135 Dauer Drive, Chapel Hill, NC 27599.

28 E-mail address: [htzhu@email.unc.edu](mailto:htzhu@email.unc.edu) Phone: (919) 966-7250

29

30 Bingxin Zhao

31 413 Academic Research Building, 265 South 37th Street, Philadelphia, PA 19104.

32 E-mail address: [bxzhao@upenn.edu](mailto:bxzhao@upenn.edu) Phone: (215) 898-8222

1 **Abstract**

2 Functional and morphological architectures of major human organs have been well  
3 characterized using imaging biomarkers. Nevertheless, deciphering the causal  
4 relationships between imaging biomarkers and major clinical outcomes, as well as  
5 understanding the causal interplay across multiple organs, remains a formidable  
6 challenge. Mendelian randomization (MR) presents a framework for inferring causality by  
7 using genetic variants as instrumental variables. Here we report a systematic multi-organ  
8 MR analysis between 402 imaging biomarkers and 88 clinical outcomes. We identified 488  
9 genetic causal links for 62 diseases and 130 imaging biomarkers from 9 organs, tissue, or  
10 systems, including the brain, heart, liver, kidney, lung, pancreas, spleen, adipose tissue,  
11 and skeleton system. We prioritized crucial intra-organ causal connections, such as the  
12 bidirectional genetic links between Alzheimer’s disease and brain function, as well as  
13 inter-organ causal effects, such as the adverse impact of heart diseases on brain health.  
14 Our findings uncover the genetic causal links spanning multiple organs, offering a more  
15 profound understanding of the intricate relationships between organ imaging biomarkers  
16 and clinical outcomes.

17

18 **Keywords:** Brain imaging; Clinical outcomes; FinnGen; GWAS; Heart imaging; Mendelian  
19 randomization; MRI; Organ imaging; UK Biobank.

1 Medical images, such as magnetic resonance imaging (MRI), provide noninvasive  
2 assessments of the health of major human organs, such as the brain, heart, liver, and  
3 kidney. Imaging biomarkers have been widely used in clinical research and applications.  
4 For example, Alzheimer's disease-related abnormalities have been consistently observed  
5 in structural and functional imaging traits extracted from brain MRI, especially in the  
6 hippocampal region<sup>1</sup>. The cardiovascular MRI (CMR) provides reliable information on  
7 alterations in ventricular function, cardiovascular morphology, and myocardial perfusion,  
8 all of which are closely related to cardiovascular diseases<sup>2</sup>. Skeleton dual-energy X-ray  
9 absorptiometry (DXA) helps discover novel genetic variants which influence the human  
10 skeletal form and uncover a major evolutionary aspect of human anatomical change to  
11 pathogenesis<sup>3</sup>. Several large-scale organ imaging datasets (on the scale of over 10,000  
12 participants) have recently been made publicly available, revealing details about human  
13 organ morphology and function<sup>4-8</sup>. A variety of complex traits and clinical outcomes are  
14 found to be associated with organ imaging biomarkers based on these well-powered  
15 population-based studies<sup>9,10</sup>. Despite these efforts, due to the inherent limitations of  
16 observational data, it remains challenging to definitively determine causal relationships  
17 between imaging biomarkers and clinical outcomes, as well as to fully understand the  
18 causal interconnections across multiple organs<sup>11</sup>.

19  
20 By using genetic variants as instrumental variables, Mendelian randomization (MR) can  
21 infer causality from observational data<sup>12,13</sup>. With assumptions regarding genetic,  
22 exposure, and outcome variables, MR aims to examine causal relationships between the  
23 exposure and the outcome variables while controlling for unwanted confounding factors.  
24 Family and population-based studies have shown that many imaging biomarkers and  
25 complex diseases are strongly influenced by genetics, with hundreds of associated genetic  
26 loci being identified in large-scale genome-wide association studies (GWAS)<sup>8,14-29</sup>.  
27 Leveraging these GWAS summary-level data (summary statistics), MR methods can  
28 uncover causality between imaging measurements and clinical endpoints. Several recent  
29 MR studies have examined the genetic causality of imaging biomarkers<sup>11,30-35</sup>. The major  
30 limitation of most of these MR studies has been focusing on one single organ (or imaging  
31 modality) and/or one single disease, or diseases in one single domain, such as brain  
32 imaging and psychiatric disorders<sup>30</sup>. It is known, however, that many diseases serve as the

1 causes and/or consequences of functional and structural changes in multiple organs of  
2 the human body. Cross-organ analysis aids in understanding the complexity of human  
3 physiology, subsequently enhancing our ability to diagnose, treat, and prevent a variety  
4 of diseases. Therefore, MR analysis from a multi-organ perspective is needed to uncover  
5 the clinical implications of imaging biomarkers in the context of the complex interplays of  
6 organ systems.

7

8 In this paper, we performed a systematic two-sample MR analysis of multi-organ images  
9 and clinical endpoints. We aggregated GWAS summary statistics from 402 multi-organ  
10 imaging biomarkers (average sample size  $n \approx 35,000$ ) from the UK Biobank (UKB)<sup>36</sup> study  
11 and 88 clinical outcomes (number of cases  $> 10,000$ ) collected by the FinnGen project<sup>27</sup>  
12 (**Fig. S1** and **Tables S1-S2**). Specifically, we examined three major brain MRI modalities: 1)  
13 101 regional brain volumes<sup>21</sup> from brain structural MRI (sMRI); 2) 110 diffusion tensor  
14 imaging (DTI) parameters<sup>23</sup> from brain diffusion MRI (dMRI); and 3) 90 functional activity  
15 (amplitude<sup>37</sup>) and connectivity traits from functional MRI (fMRI)<sup>25</sup>. In addition, we used  
16 82 CMR traits extracted from short-axis, long-axis, and aortic cine cardiac MRI<sup>38,39</sup>. We  
17 also evaluated 11 abdominal MRI biomarkers, which gauged the volume, fat, or iron  
18 content in seven organs and tissues<sup>8</sup>, as well as eight DXA imaging biomarkers that  
19 measured the lengths of all long bones and the width of the hip and shoulder<sup>29</sup>. The  
20 **Methods** section provides more details on these multi-organ imaging biomarkers. We  
21 applied 8 MR methods<sup>40-48</sup> to explore the bidirectional genetic causal links. The study  
22 design is presented in **Figure 1A** and a high-level summary of our findings can be found in  
23 **Figure 1B**.

24

## 25 **RESULTS**

### 26 **Genetic causality between brain imaging and multi-organ diseases**

27 In this section, we examined the causal relationship between brain imaging biomarkers  
28 and multi-organ diseases. At the Bonferroni significance level ( $P < 5.18 \times 10^{-6}$ , multiple  
29 testing adjustment for both directions), MR suggested 127 significant genetic causal  
30 effects on 58 brain imaging biomarkers from 20 diseases in 8 major categories, including  
31 mental and behavioral disorders, diseases of the nervous system, diseases of the  
32 circulatory system, cardiometabolic endpoints, interstitial lung disease endpoints,

1 diseases marked as autoimmune origin, diseases of the eye and adnexa, and diseases of  
2 the genitourinary system (**Fig. S2** and **Table S3**). Among all the diseases, heart-related  
3 diseases were the most frequent (66/127) and were predominantly associated with DTI  
4 parameters and a smaller number of regional brain volumes. No significant causal effects  
5 were observed from heart diseases to fMRI traits. The top three heart diseases that  
6 exhibited causal genetic impacts on brain structures included peripheral artery disease  
7 (15/66), hypertension (14/66), and hypertensive diseases (12/66) (**Figs. S2-S4**). For  
8 example, peripheral artery disease played a causal role in altering the white matter  
9 microstructure within the anterior limb of the internal capsule (ALIC,  $|\beta| > 0.15$ ,  $P <$   
10  $3.04 \times 10^{-8}$ ), the body of corpus callosum tract (BCC,  $|\beta| > 0.14$ ,  $P < 8.44 \times 10^{-7}$ ), and the genu  
11 of corpus callosum tract (GCC,  $|\beta| > 0.13$ ,  $P < 4.24 \times 10^{-6}$ ). Hypertension and hypertensive  
12 diseases were causally associated with the superior corona radiata (SCR,  $|\beta| > 0.07$ ,  $P <$   
13  $9.47 \times 10^{-8}$ ). In addition to DTI parameters, hypertension also negatively affected the total  
14 grey matter volume ( $|\beta| > 0.02$ ,  $P < 1.26 \times 10^{-8}$ ) (**Figs. 2C** and **S2-S3**). In addition to heart-  
15 related diseases, several other non-neurological clinical endpoints also influenced brain  
16 health. For example, negative causal effects of asthma were found on the SCR ( $|\beta| > 0.05$ ,  
17  $P < 7.26 \times 10^{-7}$ ) and volume of the right inferior lateral ventricle ( $|\beta| > 0.09$ ,  $P < 8.66 \times 10^{-7}$ )  
18 (**Fig. S5**).

19  
20 Brain disorders also causally affected the brain imaging biomarkers (49/127), with  
21 dementia and Alzheimer's disease being the most common brain-related diseases (**Fig.**  
22 **S2**). Interestingly, brain disorders were primarily associated with fMRI traits. For example,  
23 Alzheimer's disease was consistently found to be causally related to decreased functional  
24 activity in the dorsal attention ( $|\beta| > 0.04$ ,  $P < 5.07 \times 10^{-8}$ ), frontoparietal, and secondary  
25 visual network ( $|\beta| > 0.04$ ,  $P < 4.70 \times 10^{-8}$ ), as well as DTI parameters of the SCR ( $|\beta| > 0.03$ ,  
26  $P < 1.85 \times 10^{-6}$ ) (**Figs. 2A** and **S6**). Both functional MRI and DTI parameters have been  
27 extensively used to study Alzheimer's disease<sup>49</sup>. Abnormalities in white matter, such as  
28 those in the left SCR, as well as decreased functional connectivity in attention-related  
29 networks, have been identified in patients with Alzheimer's disease<sup>50,51</sup>. Similar to  
30 Alzheimer's disease, dementia demonstrated negative causal genetic effects on  
31 functional activity in multiple networks, including the cingulo-opercular, default mode,  
32 dorsal attention, frontoparietal, language, posterior multimodal, and secondary visual

1 networks ( $|\beta| > 0.12$ ,  $P < 4.74 \times 10^{-8}$ ) (**Figs. 2B** and **S7**). In addition, mood disorders affected  
2 brain volume traits, such as the left and right putamen ( $|\beta| > 0.04$ ,  $P < 5.64 \times 10^{-7}$ ) (**Fig. S8**).  
3 More results on causal genetic links from clinical endpoints to brain imaging traits were  
4 summarized in **Figures S3-S9**.

5

6 Brain and other organ diseases may also be caused by structural or functional changes in  
7 the brain. We investigated this direction by using brain imaging traits as exposure  
8 variables and clinical endpoints as the outcome variables. At the Bonferroni significance  
9 level ( $P < 5.18 \times 10^{-6}$ ), we found 85 significant pairs between 22 brain imaging biomarkers  
10 and 20 clinical endpoints (**Fig. S10** and **Table S3**). Most of the significant imaging-disease  
11 pairs were related to fMRI traits. Specifically, 66 of the 85 pairs were associated with fMRI  
12 traits, 10 with DTI parameters, and 9 with regional brain volumes. The majority of the  
13 significant findings were related to brain diseases (65/85), with a minor proportion linked  
14 to heart diseases (13/85), autoimmune diseases (4/85), COPD and related endpoints  
15 (1/85), diseases of the eye and adnexa (1/85), and diseases of the genitourinary system  
16 (1/85). For example, decreased activity in multiple functional networks was related to a  
17 higher risk of Alzheimer's disease, such as the default mode and dorsal-attention  
18 networks ( $|\beta| > 0.5$ ,  $P < 5.65 \times 10^{-13}$ ) (**Figs. 3A** and **S11**). We also identified genetic causal  
19 effects from DTI parameters on Alzheimer's disease, such as the BCC and SCR ( $|\beta| > 0.49$ ,  
20  $P < 6.79 \times 10^{-7}$ ) (**Figs. 3A** and **S11**).

21

22 Dementia exhibited a similar pattern to Alzheimer's disease, being causally influenced by  
23 decreased activity in multiple networks, such as the default mode, dorsal-attention, and  
24 secondary visual network ( $|\beta| > 0.002$ ,  $P < 2.77 \times 10^{-7}$ ) (**Fig. 3B** and **S12**). fMRI traits,  
25 including the functional activity of the secondary visual network and functional  
26 connectivity of the default mode network, were also causally linked to other brain  
27 diseases, such as neuropsychiatric disorders ( $|\beta| > 0.09$ ,  $P < 8.88 \times 10^{-16}$ ) and neurological  
28 diseases ( $|\beta| > 0.06$ ,  $P < 1.72 \times 10^{-6}$ ) (**Figs. S13** and **S14**). Finally, we found that brain  
29 structural alterations may also influence other non-neurological diseases. For example,  
30 the left basal forebrain posed a negative causal effect on hypertensive diseases ( $|\beta| > 0.12$ ,  
31  $P < 8.47 \times 10^{-9}$ ) and hypertension ( $|\beta| > 0.15$ ,  $P < 6.19 \times 10^{-11}$ ). The left lingual negatively  
32 affected female genital prolapse ( $|\beta| > 0.75$ ,  $P < 8.68 \times 10^{-7}$ ).

1

## 2 **Causal genetic relationships between CMR traits and clinical outcomes**

3 We first examined the causal effects from clinical endpoints to CMR measures of heart  
4 structure and function. We identified 111 significant results at the Bonferroni significance  
5 level ( $P < 6.85 \times 10^{-6}$ ), covering 41 unique CMR traits of the ascending aorta (AAo),  
6 descending aorta (DAo), left atrium (LA), and left ventricle (LV). Significant causal effects  
7 were found from 13 unique clinical endpoints in three categories: diseases of the  
8 circulatory system (8/13), cardiometabolic endpoints (4/13), as well as COPD and related  
9 endpoints (1/13). The majority of significant findings were related to heart-related  
10 diseases, with 66 out of 111 being diseases of the circulatory system and 44 out of 111  
11 being cardiometabolic endpoints (**Fig. S15** and **Table S4**).

12

13 The most frequently observed genetic effects were related to hypertensive diseases and  
14 hypertension (**Figs. 4A** and **S16**). Specifically, hypertensive diseases had negative causal  
15 effects on AAo and DAo distensibility ( $|\beta| > 0.10$ ,  $P < 1.26 \times 10^{-7}$ ), whose genetic  
16 associations have been found in previous studies<sup>52-54</sup>. Hypertensive diseases also affected  
17 LV and LA traits, such as the global radial strain ( $|\beta| > 0.06$ ,  $P < 4.47 \times 10^{-9}$ ), LA stroke  
18 volume ( $|\beta| > 0.07$ ,  $P < 3.04 \times 10^{-8}$ ), and LV myocardial mass ( $|\beta| > 0.11$ ,  $P < 3.04 \times 10^{-15}$ ).  
19 These findings were consistent with previous results derived from genetic association  
20 studies<sup>55,56</sup>. Hypertension exhibited a similar pattern to hypertensive diseases, having a  
21 causal impact on various AAo and DAo traits, such as DAo distensibility, along with LA and  
22 LV traits, such as the LA minimum volume (LA<sub>min</sub> volume,  $|\beta| > 0.03$ ,  $P < 7.11 \times 10^{-6}$ ).

23

24 In addition, angina pectoris causally influenced AAo maximum and minimum areas  
25 (AAo<sub>max</sub> and AAo<sub>min</sub> areas,  $|\beta| > 0.71$ ,  $P < 1.44 \times 10^{-7}$ ). The aortic aneurysm had a positive  
26 causal effect on DAo maximum and minimum areas (DAo<sub>max</sub> and DAo<sub>min</sub> areas,  $|\beta| > 0.71$ ,  
27  $P < 1.63 \times 10^{-24}$ ) and AAo<sub>max</sub> and AAo<sub>min</sub> areas ( $|\beta| > 0.16$ ,  $P < 2.22 \times 10^{-6}$ ). These results align  
28 with clinical observations. Atrial fibrillation and flutter mainly affected LA traits, such as  
29 the LA ejection fraction ( $|\beta| > 0.07$ ,  $P < 5.88 \times 10^{-8}$ ), LA maximum volume (LA<sub>max</sub> volume,  
30  $|\beta| > 0.07$ ,  $P < 1.62 \times 10^{-6}$ ), and LA<sub>min</sub> volume ( $|\beta| > 0.08$ ,  $P < 8.26 \times 10^{-8}$ ). Atrial fibrillation is  
31 considered to result in a decrease in ejection fraction as well as an increase in LA  
32 volumes<sup>57,58</sup>. In addition to heart-related diseases, COPD and related endpoints were

1 found to influence CMR traits, such as the negative effect of COPD on  $DAo_{max}$  area  
2 ( $|\beta| > 0.10$ ,  $P < 4.45 \times 10^{-11}$ , and **Fig. S16**). Emphysema, a form of COPD distinguished by the  
3 degradation of lung tissue, may contribute to the dilatation of the thoracic aorta<sup>59</sup>. This  
4 could be attributed to emphysema's involvement in the degradation of elastic fibers  
5 within the lungs, potentially triggering alterations in the aortic wall's elasticity<sup>60</sup>. Such  
6 changes may precipitate the dilatation or ballooning of the thoracic aorta, thereby  
7 escalating the risk of both aortic aneurysm and abdominal aortic abnormalities<sup>59</sup>. This  
8 elucidates the potential biological mechanisms driving these causal relationships.

9

10 On the other hand, structural and functional irregularities of the heart may increase the  
11 risk of multi-organ diseases, given that the heart pumps blood to all other organs to  
12 maintain their functions<sup>61</sup>. We tested this direction by treating CMR traits as exposure  
13 variables and clinical endpoints as the outcomes. After Bonferroni adjustment ( $P <$   
14  $6.85 \times 10^{-6}$ ), we found 27 significant causal pairs, 25 for heart-related diseases and 2 for  
15 autoimmune diseases (**Fig. S17** and **Table S4**). For example, global peak circumferential  
16 strain was positively linked to heart failure and antihypertensive medication ( $|\beta| > 0.51$ ,  $P$   
17  $< 8.49 \times 10^{-8}$ ), while LV ejection fraction had a negative causal effect on these conditions  
18 ( $|\beta| > 0.55$ ,  $P < 1.12 \times 10^{-6}$ ). In addition to heart-related diseases, heart structural changes  
19 affected diseases marked as autoimmune origin. For example, right ventricular end-  
20 systolic volume had a negative causal effect on the autoimmune diseases defined by  
21 Finngen<sup>27</sup> ( $|\beta| > 0.18$ ,  $P < 3.10 \times 10^{-6}$ ) (**Figs. 4B** and **S18**). In summary, we discovered causal  
22 relationships between CMR traits and heart-related diseases, which were typically  
23 bidirectional. Additionally, we revealed the inter-organ causal relationships between the  
24 heart and other organs.

25

## 26 **Causal genetic links between abdominal imaging biomarkers and clinical outcomes**

27 We first examined the effects of multi-organ diseases on abdominal imaging biomarkers,  
28 such as the volume or iron content of the spleen, kidney, liver, lung, and pancreas<sup>8</sup>. At the  
29 Bonferroni significance level ( $P < 6.69 \times 10^{-5}$ ), we discovered 51 significant causal pairs  
30 from multi-organ diseases to abdominal imaging biomarkers, with liver imaging traits  
31 being the most impacted (26/51). Brain-related diseases were the most prevalent among  
32 all significant findings (35/51), followed by heart-related diseases (7/51), rheumatoid



1 endpoints (4/51), diseases of the eye and adnexa (3/51), and autoimmune diseases (2/51)  
2 (**Fig. S19** and **Table S5**). These findings were in line with ongoing research on the interplay  
3 between the brain and abdominal organs, such as the brain-gut connection<sup>62-64</sup>, brain-  
4 kidney connection<sup>65,66</sup>, and brain-liver connection<sup>67</sup>.

5

6 Alzheimer's disease and dementia were consistently found to be causally linked with  
7 various abdominal imaging biomarkers, such as the percent liver fat ( $|\beta| > 0.37$ ,  $P <$   
8  $4.96 \times 10^{-6}$ ), liver volume ( $|\beta| > 0.03$ ,  $P < 5.88 \times 10^{-5}$ ), and adipose tissue measurement  
9 ( $|\beta| > 0.06$ ,  $P < 3.13 \times 10^{-5}$ ). In addition to Alzheimer's disease and dementia, there were  
10 multiple other brain-related diseases that may affect abdominal organs, including mental  
11 and behavioral disorders due to alcohol and psychoactive substance use, as well as sleep  
12 apnoea. For example, sleep apnoea influenced several abdominal traits, such as the liver  
13 volume ( $|\beta| > 0.11$ ,  $P < 2.80 \times 10^{-5}$ ) and kidney volume ( $|\beta| > 0.23$ ,  $P < 2.57 \times 10^{-6}$ ). Sleep  
14 apnea can lead to renal damage caused by ischemic stress, hemodynamic changes, or  
15 intermediary conditions such as hypertension, which can result in early chronic kidney  
16 disease<sup>68,69</sup>. Multiple heart-related diseases also genetically impacted abdominal organs.  
17 For example, heart failure and antihypertensive medication can lead to larger spleen  
18 volume ( $|\beta| > 0.004$ ,  $P < 2.66 \times 10^{-6}$ ). It has been found that heart splenic enlargement often  
19 results from blood stasis and right heart disease is often accompanied by splenomegaly<sup>70</sup>.  
20 Atherosclerosis was causally linked to the pancreas iron content, which was also  
21 supported by clinical evidence<sup>71,72</sup>.

22

23 In addition to brain and heart-related diseases, we also observed causal effects from  
24 other diseases, such as autoimmune diseases on spleen volume and liver iron content.  
25 The spleen, as the largest immune organ in the body, can become enlarged because of  
26 various rheumatic and immune system diseases, such as systemic lupus erythematosus,  
27 Felty's syndrome, sarcoidosis, and autoimmune hepatitis<sup>73-76</sup>. Liver iron content causally  
28 related to both autoimmune and rheumatological diseases ( $|\beta| > 0.10$ ,  $P < 3.02 \times 10^{-5}$ ). It  
29 has been found that excessive deposition of iron ions exists in the affected tissues of  
30 autoimmune diseases, such as brain tissues of multiple sclerosis patients and synovial  
31 fluid of patients with rheumatoid arthritis<sup>77</sup>. Disorders of the choroid and retina, as well  
32 as the eye and adnexa diseases, were also found to be causally linked to liver iron content

1 ( $|\beta| > 0.10$ ,  $P < 6.48 \times 10^{-5}$ , **Figs. 5A and S20**). Metal tends to accumulate in human ocular  
2 tissues, particularly in the choroid and retinal pigment epithelium<sup>78</sup>.

3

4 Next, we tested the opposite direction that abdominal imaging biomarkers being the  
5 exposure variables and multi-organ diseases being the outcomes. At the Bonferroni  
6 significance level ( $P < 6.69 \times 10^{-5}$ ), we identified 55 significant pairs, with heart-related  
7 diseases being the most prevalent (34/55), followed by brain-related diseases (11/55),  
8 diseases marked as autoimmune origin (2/55), diseases of the eye and adnexa (5/55), and  
9 diseases of the genitourinary system (3/55) (**Fig. S21 and Table S5**). For example, pancreas  
10 fat causally affected the deep vein thrombosis of lower extremities and pulmonary  
11 embolism ( $|\beta| > 0.38$ ,  $P < 1.04 \times 10^{-12}$ ). A reduction in pancreatic fat content may directly  
12 improve cellular function and insulin secretion rate, affecting triglyceride levels and blood  
13 flow<sup>79</sup>.

14

15 Larger liver, spleen, and kidney volumes were all causally linked to heart-related diseases  
16 (**Fig. 5B and S22**). Specifically, a larger liver volume was causally linked to hypertensive  
17 diseases and hypertension ( $|\beta| > 0.13$ ,  $P < 1.19 \times 10^{-10}$ ); a larger kidney volume was causally  
18 related to a higher risk of stroke ( $|\beta| > 0.25$ ,  $P < 3.33 \times 10^{-5}$ ); and a larger spleen volume  
19 had causal effects on various heart-related diseases, including coronary angioplasty  
20 ( $|\beta| > 0.14$ ,  $P < 4.94 \times 10^{-7}$ ), coronary atherosclerosis ( $|\beta| > 0.07$ ,  $P < 6.94 \times 10^{-10}$ ), and  
21 peripheral artery diseases ( $|\beta| > 0.21$ ,  $P < 4.98 \times 10^{-5}$ ). In nephrotic syndrome, platelet over-  
22 activation and the use of diuretics and glucocorticoids can aggravate hypercoagulability.  
23 Therefore, kidney diseases, especially nephrotic syndrome, are prone to thrombotic and  
24 embolic complications, which can lead to stroke<sup>80-82</sup>. For brain-related disorders, we  
25 detected causal effects from liver volume to alcohol use disorder, as well as mental and  
26 behavioral disorders due to alcohol and psychoactive substance use. In addition, percent  
27 liver fat had causal links with Alzheimer's disease, dementia, and psychiatric diseases.  
28 Previous studies have reported that non-alcoholic fatty liver disease contributes to  
29 neurological conditions like cognitive impairment and memory loss via insulin resistance  
30 and inflammation, along with excessive cytokine secretion<sup>83-86</sup>. In summary, we found  
31 that brain-related disorders result in alterations in abdominal organs. Furthermore,  
32 bidirectional relationships are observed in both neurodegenerative and psychiatric

1 disorders. On the other hand, multiple abdominal organs are causally linked to heart-  
2 related diseases.

3

#### 4 **Causal genetic links between skeleton DXA traits and clinical outcomes**

5 We first identified the causal effects of multiple organ diseases on DXA-derived skeleton  
6 traits<sup>3</sup>. At the Bonferroni significance level ( $P < 3.39 \times 10^{-5}$ ), we found strong evidence that  
7 multi-organ diseases affected the human skeleton health, where heart-related diseases  
8 (6/12) and diseases of the nervous system (4/12) were the majority, as well as rheumatic  
9 disease (1/12) and diseases of the genitourinary system (1/12) (**Fig. S23** and **Table S6**).  
10 Carpal tunnel syndrome ( $|\beta| > 0.0007$ ,  $P < 6.25 \times 10^{-8}$ ) and sleep apnoea ( $|\beta| > 0.001$ ,  $P <$   
11  $6.35 \times 10^{-8}$ ) were causally related to higher average forearm length. Carpal tunnel  
12 syndrome is when the median nerve (nerve from the forearm to the palm of the hand)  
13 becomes pressed or squeezed, which affects the wrist-to-forearm ratio<sup>87,88</sup>. It has been  
14 observed that oral appliance therapy<sup>89</sup>, which is an effective treatment of sleep apnea, is  
15 associated with skeletal changes<sup>90</sup>. Furthermore, the nerve, nerve root, and plexus  
16 disorders were causally linked with higher average tibia length ( $|\beta| > 0.001$ ,  $P < 2.78 \times 10^{-$   
17  $5$ ), which was consistent with the previous finding that a specific type of plexus disorder,  
18 lumbosacral plexus disorder, is associated with lower leg<sup>91</sup>. Heart-related diseases also  
19 had causal effects on several DXA traits. For example, coronary heart disease had a  
20 negative causal effect on the average tibia length ( $|\beta| > 0.0002$ ,  $P < 2.50 \times 10^{-5}$ ) and a  
21 positive causal effect on the hip width ( $|\beta| > 0.0004$ ,  $P < 1.68 \times 10^{-5}$ ). Additionally,  
22 gonarthrosis affected the average tibia length ( $|\beta| > 0.0005$ ,  $P < 1.69 \times 10^{-5}$ ) (**Figs. 6A** and  
23 **S24**).

24

25 The skeletal system serves as the foundational support for the human body, and therefore,  
26 skeletal abnormalities may potentially contribute to risk of multi-organ diseases. We  
27 identified 17 causal pairs at the Bonferroni significance level ( $P < 3.39 \times 10^{-5}$ ). More than  
28 half (10/17) of these results were related to the heart, and the rest were rheumatic  
29 disease (3/17), diseases of the eye and adnexa (2/17), interstitial lung diseases (1/17), and  
30 diseases of the genitourinary system (1/17) (**Fig. S23** and **Table S6**). Average tibia length  
31 was causally linked to coxarthrosis ( $|\beta| > 30.03$ ,  $P < 3.11 \times 10^{-9}$ ), gonarthrosis ( $|\beta| > 19.39$ ,  $P$   
32  $< 3.18 \times 10^{-7}$ ), and other rheumatological endpoints ( $|\beta| > 13.12$ ,  $P < 2.74 \times 10^{-5}$ ). It has been

1 found that the leg length discrepancy could lead to lower limb biomechanics, such as  
2 gonarthrosis, coxarthrosis, and other lower limb symptoms<sup>92,93</sup>. Torso length causally  
3 affected heart-related issues, such as coronary angioplasty ( $|\beta| > 38.85$ ,  $P < 9.45 \times 10^{-5}$ ),  
4 coronary atherosclerosis ( $|\beta| > 22.94$ ,  $P < 1.22 \times 10^{-5}$ ), hard cardiovascular diseases  
5 ( $|\beta| > 18.12$ ,  $P < 1.30 \times 10^{-5}$ ), and ischemic heart diseases ( $|\beta| > 30.99$ ,  $P < 1.33 \times 10^{-5}$ ).  
6 Previous studies examining the relationship between skeletal length and heart diseases  
7 have primarily focused on leg length or overall body height, generally reporting negative  
8 associations<sup>94,95</sup>. Consistent with these associations, we found that a long torso can lead  
9 to a higher risk of heart disease. We also observed higher average tibia length to be  
10 causally linked to a lower risk of hypertension ( $|\beta| > 6.46$ ,  $P < 1.27 \times 10^{-7}$ ), which was in line  
11 with previous findings<sup>96</sup> (**Figs. 6B** and **S25**). In conclusion, we found that rheumatoid  
12 endpoints (such as gonarthrosis) and diseases of the nervous system (such as nerve, nerve  
13 root, and plexus disorders) had a significant impact on bone health. Conversely, skeletal  
14 traits, like torso length, demonstrated a causal link with heart diseases.

15

## 16 **Discussion**

17 Observational studies have established numerous links between various imaging-derived  
18 phenotypes and clinical outcomes. However, these associations are frequently influenced  
19 by residual confounding, complicating the accurate inference of causal effect sizes<sup>97</sup>. MR  
20 allows for the inference of causal relationships between exposure and outcome variables.  
21 MR leverages the natural and random assortment of genetic variants during meiosis,  
22 making these variants an ideal choice as instrumental variables to discern causal effects.  
23 In the present study, we evaluated the causal relationship between 402 multi-organ  
24 imaging biomarkers and 88 clinical outcomes through bidirectional MR. To avoid the issue  
25 of sample overlap<sup>98</sup>, which may bias the causal effect and has sometimes been overlooked  
26 in many current MR-based studies, we used a two-sample MR design and sourced our  
27 imaging and clinical data from different large-scale cohorts.

28

29 It is widely understood that diseases often affect more than just one part of the human  
30 body, given the interdependent nature of our organ systems for overall body function.  
31 The brain and heart are particularly important among all organs, as the brain manages a  
32 range of functions, including reactions, emotions, vision, memory, and cognition<sup>99,100</sup>

1 while the heart serves as the engine of the body, pumping life-sustaining blood through  
2 a network of arteries and veins to supply other organs with the oxygen and nutrients they  
3 need. Dysfunctions in various organs can potentially have adverse effects on the brain  
4 and heart. Similarly, abnormalities within the brain and heart can result in dysfunction in  
5 other parts of the body. Our results support the presence of robust bidirectional  
6 interactions between the brain and heart with other organs. In addition to the  
7 connections to the brain and heart, we also discovered many other causal relationships  
8 for other organs. The interaction plot across different organ systems can be found in  
9 **Figure 1B**. Below we provide more detailed discussions of these specific findings.

10

#### 11 *Intra-brain causal connections.*

12 Variations in brain structure and function were closely linked with brain disorders, with  
13 parts of these relationships appearing to be bidirectional. We consistently found causal  
14 links between brain imaging biomarkers and multiple psychiatric disorders or neurological  
15 diseases, such as Alzheimer's disease, dementia, mood disorder, and sleep apnea. For  
16 example, Alzheimer's disease and dementia had bidirectional causal links with fMRI traits  
17 and DTI parameters. Previous studies have consistently shown that resting fMRI  
18 connectivity patterns are altered in patients with Alzheimer's disease<sup>101,102</sup>, especially in  
19 brain regions involved in memory and cognitive function<sup>103,104</sup>.

20

#### 21 *Brain-heart causal connections.*

22 While association studies have been investigating the brain-heart interaction<sup>39,105</sup>, the  
23 causal genetic links within these heart-brain systems remain largely unexplored. We  
24 discovered causal connections from several heart-related diseases such as hypertension,  
25 hypertensive diseases, heart failure, and peripheral artery disease to DTI parameters in  
26 white matter tracts such as the SCR, ALIC, BCC, GCC, the splenium of corpus callosum, and  
27 the retrolenticular part of the internal capsule (RLIC). Additionally, these diseases were  
28 also linked to regional brain volumes, such as grey matter and left amygdala.  
29 Hypertension can lead to damage of the blood vessels in the brain<sup>106</sup>, which can in turn  
30 lead to a reduction in the volume of grey matter in certain brain regions<sup>107</sup>. This may result  
31 in cognitive impairment and an increased risk of developing dementia. Therefore,  
32 effective management of hypertension through lifestyle changes and medication can help

1 reduce the risk of these negative effects on the brain. On the other hand, alterations in  
2 brain structure, such as deformations in the left ventral DC and left basal forebrain, were  
3 found to contribute to heart-related diseases like hypertension. Similarly, changes in the  
4 left superior temporal region were linked to heart failure. These could be attributed to  
5 the brain's essential function in controlling blood pressure via a sophisticated network  
6 that involves multiple regions and pathways<sup>108,109</sup>.

7

#### 8 *Bidirectional connections between the brain and abdominal organs.*

9 Brain abnormalities affected multiple abdominal organs and the skeletal system. For  
10 example, Alzheimer's disease and dementia causally affected the percent liver fat, and  
11 neurological diseases (defined by FinnGen<sup>27</sup>) had a positive causal effect on lung volume.  
12 It has been found that neurological diseases, such as multiple sclerosis, Parkinson's  
13 disease, amyotrophic lateral sclerosis, and Huntington's disease, can cause respiratory  
14 muscle weakness<sup>110,111</sup>, which can affect lung volume and function. We also found sleep  
15 apnoea may lead to larger spleen and kidney volume. This may be due to the increased  
16 workload on the spleen to filter blood and remove damaged red blood cells. Additionally,  
17 the low oxygen levels associated with sleep apnea can lead to an increase in the number  
18 of red blood cells in the body, which can also contribute to splenomegaly and a change in  
19 kidney volume. Sleep apnea was causally associated with increased pancreas iron content,  
20 potentially due to the decreased oxygen levels that accompany sleep apnea, resulting in  
21 increased iron absorption in the body. The excess iron in the pancreas can lead to  
22 oxidative stress and inflammation<sup>112,113</sup>, which can contribute to the development of  
23 pancreatic damage and dysfunction<sup>114-116</sup>.

24

25 In addition to the aforementioned neurological diseases, we also discovered that mental  
26 and behavioral disorders attributed to alcohol can lead to an increase in percent liver fat.  
27 It has been found that people with alcohol use disorder are more likely to develop  
28 alcoholic fatty liver disease<sup>117</sup>. Besides brain-related diseases, brain structural  
29 alternations could also lead to a higher risk of diseases of other organs. For example, right  
30 postcentral was causally linked to COPD. Some studies have suggested that chronic stress  
31 and anxiety, which are associated with changes in brain structure, may contribute to the  
32 development or worsening of respiratory conditions such as COPD<sup>118,119</sup>.

1

2 On the other hand, brain imaging biomarkers or disorders were causally affected by  
3 several diseases of other organs or systems. A high percent liver fat resulted in a lower  
4 risk of Alzheimer's disease and dementia. Previous studies<sup>120,121</sup> have reported  
5 associations between the two and our results aligned with the most recent study<sup>122</sup>. More  
6 work is needed to understand the underlying pathophysiological mechanism. Brain  
7 imaging biomarkers were affected by multi-organ diseases, but some of them may affect  
8 the brain indirectly, such as through mediating effects of anxiety and depression. For  
9 example, diseases of the genitourinary system (ovarian cyst and menorrhagia) causally  
10 affected brain structural features. Ovarian cysts can cause hormonal imbalances due to  
11 the production of hormones by the cysts themselves<sup>123</sup>. These hormonal imbalances can  
12 cause a range of symptoms, such as mood swings, anxiety, and depression<sup>124</sup>, which can  
13 affect brain function and emotional regulation. Diseases of the eye and adnexa  
14 (conjunctivitis) had genetic causal effects on functional connectivity traits. Conjunctivitis  
15 can be caused by a viral or bacterial infection, which can potentially lead to cause systemic  
16 inflammation in the body<sup>125</sup>. Systemic inflammation has been linked to changes in brain  
17 function and structure and may affect brain fMRI traits<sup>126,127</sup>.

18

19 In addition, asthma influenced regional brain volumes. One prevalent way in which  
20 asthma impacts the brain is via the emotional and psychological stress associated with  
21 managing a chronic illness. Anxiety, stress, and depression, often faced by individuals with  
22 asthma, can induce alterations in brain structure. Previous studies have shown that  
23 individuals with asthma may have reduced cognitive function, including impaired memory  
24 and attention, and changes in brain activity patterns during cognitive tasks<sup>128,129</sup>. Last but  
25 not least, autoimmune diseases (defined by FinnGen<sup>27</sup>) affected brain imaging biomarkers,  
26 such as DTI parameters of the RLIC and SCR. Multiple sclerosis is an autoimmune disease  
27 that affects the central nervous system, and the damage to the myelin sheath that  
28 surrounds axons can occur in various regions of the brain<sup>130,131</sup>, including the internal  
29 capsule. The damage can cause disruptions in the neural connections passing through the  
30 anterior limb, leading to symptoms such as weakness, spasticity, and difficulty with  
31 balance and coordination. In some rare autoimmune diseases, such as neuromyelitis  
32 optica<sup>132</sup> and autoimmune encephalitis, inflammation and damage can occur in the brain.

1 The resulting neurological symptoms can vary depending on the severity and location of  
2 the damage<sup>133,134</sup>. Furthermore, autoimmune diseases that cause systemic inflammation,  
3 such as rheumatoid arthritis and lupus, which can potentially affect the brain<sup>135</sup> and white  
4 matter tracts<sup>136,137</sup>. Chronic inflammation can lead to changes in the microstructure of  
5 white matter tracts, which can result in alterations in neural connectivity and  
6 function<sup>138,139</sup>.

7

#### 8 *Intra-heart causal connections.*

9 Bidirectional causal relationships were identified between heart-related diseases and  
10 CMR traits. Hypertension and hypertensive diseases were found to causally influence  
11 several CMR traits across various heart chambers and aorta regions. Conversely,  
12 variations in CMR traits were observed to potentially lead to heart diseases. These  
13 findings are in accordance with existing clinical evidence. For example, hypertension can  
14 cause the LA to enlarge, a condition known as left atrial hypertrophy<sup>140,141</sup>. This  
15 enlargement can lead to several complications, including atrial fibrillation, heart failure,  
16 and stroke<sup>142</sup>. As for atrial fibrillation, the electrical signals that control the heartbeat  
17 become chaotic, causing the heart to beat irregularly and often too fast. Over time, the  
18 constant irregularity of the heartbeat can also cause the LA to enlarge and weaken<sup>143</sup>.

19

#### 20 *Bidirectional connections between the heart and abdominal organs.*

21 Heart diseases and various multi-organ imaging biomarkers were causally related. For  
22 instance, heart failure was found to cause an increase in spleen volume. When the heart  
23 is not able to pump blood effectively, it can cause an increase in the pressure from the  
24 veins to the spleen. This increased pressure can cause the spleen to enlarge, a condition  
25 known as splenomegaly<sup>144</sup>. In addition, the backup of blood in the liver that can occur  
26 with heart failure can also contribute to the development of splenomegaly. Larger spleen  
27 volume can conversely lead to heart failure. An enlarged spleen can increase the workload  
28 on the heart, leading to further worsening of heart failure symptoms.

29

30 Pancreas was also found to have a causal effect on the heart. For example, excess  
31 pancreas fat was found to cause a higher risk of developing deep vein thrombosis of lower  
32 extremities and pulmonary embolism. Pancreatic steatosis is a condition where fat



1 accumulates in the pancreas. This is associated with a number of metabolic abnormalities,  
2 including insulin resistance and inflammation, which can contribute to the development  
3 of cardiovascular disease<sup>145,146</sup>. The inflammatory and procoagulant effects of excess  
4 pancreatic fat could potentially contribute to an increased risk of deep vein thrombosis.

5  
6 The heart and lungs are closely connected and work together as part of the cardiovascular  
7 system. The lungs are responsible for taking in oxygen from the air we breathe and  
8 transferring it into the bloodstream, while the heart pumps the oxygen-rich blood  
9 throughout the body to nourish cells and tissues. We found strong evidence of causal links  
10 from COPD and CMR traits of DAo. The degradation of elastic fibers through proteolysis  
11 is a characteristic of emphysema<sup>147</sup>, which can potentially lead to the enlargement of the  
12 thoracic aorta.

13  
14 Spleen, as the largest immune organ, is closely related with diseases marked as  
15 autoimmune origin. We found strong evidence showing the genetic causal relationship  
16 between spleen volume and autoimmune diseases (defined by Finngen<sup>27</sup>), such as  
17 rheumatoid arthritis, systemic lupus erythematosus, and systemic sclerosis. It has been  
18 reported that autoimmune diseases can affect the spleen. For instance, conditions like  
19 lupus or rheumatoid arthritis can lead to splenomegaly, a condition often triggered by  
20 inflammation or the accumulation of abnormal immune cells in the spleen<sup>148,149</sup>.

## 21 22 Skeleton DXA traits.

23 We also found genetic causal links between skeleton DXA traits and multiple organ  
24 diseases. Skeleton traits were causally affected by diseases of the nervous system,  
25 rheumatic disease, as well as nerve, nerve root and plexus disorders. Heart diseases may  
26 also impact the skeletal system by influencing bone health. It has been observed that  
27 individuals with heart disease, especially those with heart failure, have an increased risk  
28 of osteoporosis and bone fractures<sup>149,150</sup>. This may be due to a variety of factors. For  
29 example, some medications used to treat heart diseases, such as diuretics and steroids,  
30 can also increase the risk of osteoporosis<sup>151</sup>. Additionally, individuals with heart disease  
31 may have reduced mobility and physical activity, which can lead to decreased bone  
32 density and strength<sup>152</sup>. Skeleton problems could also inversely contribute to numerous

1 organ diseases, with heart conditions being the most prevalent in our analysis. A long  
2 torso may lead to a high risk of coronary heart disease. We also noted that a higher  
3 average tibia length was causally associated with a lower risk of hypertension, a finding  
4 that aligns with clinical observations<sup>96</sup>.

5

#### 6 Limitations and conclusions.

7 Our study has several limitations. First, we collected GWAS summary statistics from  
8 publicly available databases, meaning that we were not able to evaluate the impact of  
9 unobserved confounders (such as population stratification) on our results. Second, one  
10 common limitation of most existing MR methods is that they require several model  
11 assumptions, and thus may suffer from model misspecifications and data heterogeneity  
12 issues when integrating data from different data resources<sup>153</sup>. We have systematically  
13 applied quality control measures and conducted sensitivity analyses in our study. Future  
14 research implementing more advanced MR methods may relax some of the model  
15 assumptions the current MR methods have made<sup>154,155</sup>. Furthermore, MR studies are  
16 designed to examine the effects of lifetime exposure factors on outcomes, not  
17 interventions within a specified period. As such, our findings may have different  
18 interpretations from rigorous results obtained from randomized controlled trials.  
19 Therefore, any clinical interventions based on these MR findings should be undertaken  
20 with caution.

21

22 In conclusion, we used two-sample bidirectional MR analyses to comprehensively explore  
23 the multi-organ causal connections between 88 clinical outcomes and 402 image-derived  
24 phenotypes of various organ systems. Our results revealed robust genetic evidence  
25 supporting causal connections within and across multiple organs. This will aid in  
26 unraveling complex pathogenic mechanisms and will contribute to the early prediction  
27 and prevention of multi-organ diseases from a whole body perspective.

28

## 29 **METHODS**

30 Methods are available in the **Methods** section.

31 *Note: One supplementary pdf file and one supplementary table zip file are available.*

32

## 1 **ACKNOWLEDGEMENTS**

2 The study has been partially supported by funding from the Wharton Dean's Research  
3 Fund and Analytics at Wharton, as well as start-up funds from Purdue Statistics  
4 Department. This research has been conducted using summary-level data from the UK  
5 Biobank study and FinnGen research project. We would like to thank the individuals who  
6 represented themselves in the UK Biobank and FinnGen studies for their participation and  
7 the research teams for their efforts in collecting, processing, and disseminating these  
8 datasets. We would like to thank the research computing groups at the University of  
9 North Carolina at Chapel Hill, Purdue University, and the Wharton School of the University  
10 of Pennsylvania for providing computational resources and support that have contributed  
11 to these research results.

12

## 13 **AUTHOR CONTRIBUTIONS**

14 J.S. and B.Z. designed the study. J.S., R.Z., C.C., B.L., Z. F., X.Y., Y.Y, X.W., and Y.L. analyzed  
15 the data. B.X., T.L., and H.Z. provided feedback on the results. J.S. and B.Z. wrote the  
16 manuscript with feedback from all authors.

17

18 **CORRESPONDENCE AND REQUESTS FOR MATERIALS** should be addressed to H.Z. and B.Z.

19

## 20 **COMPETING FINANCIAL INTERESTS**

21 The authors declare no competing financial interests.

22

## 23 **REFERENCES**

- 24 1. Buckner, R.L., *et al.* Molecular, structural, and functional characterization of  
25 Alzheimer's disease: evidence for a relationship between default activity,  
26 amyloid, and memory. *Journal of neuroscience* **25**, 7709-7717 (2005).
- 27 2. Pennell, D.J., *et al.* Clinical indications for cardiovascular magnetic resonance  
28 (CMR): Consensus Panel report. *European heart journal* **25**, 1940-1965 (2004).
- 29 3. Kun, E., *et al.* The genetic architecture of the human skeletal form. *bioRxiv*,  
30 2023.2001. 2003.521284 (2023).
- 31 4. Petersen, S.E., *et al.* UK Biobank's cardiovascular magnetic resonance protocol.  
32 *Journal of cardiovascular magnetic resonance* **18**, 1-7 (2015).

- 1 5. Littlejohns, T.J., Sudlow, C., Allen, N.E. & Collins, R. UK Biobank: opportunities for  
2 cardiovascular research. *European heart journal* **40**, 1158-1166 (2019).
- 3 6. Miller, K.L., *et al.* Multimodal population brain imaging in the UK Biobank  
4 prospective epidemiological study. *Nature Neuroscience* **19**, 1523-1536 (2016).
- 5 7. Thompson, P.M., *et al.* ENIGMA and global neuroscience: A decade of large-scale  
6 studies of the brain in health and disease across more than 40 countries.  
7 *Translational psychiatry* **10**, 1-28 (2020).
- 8 8. Liu, Y., *et al.* Genetic architecture of 11 organ traits derived from abdominal MRI  
9 using deep learning. *Elife* **10**, e65554 (2021).
- 10 9. Smith, S.M. & Nichols, T.E. Statistical challenges in “big data” human  
11 neuroimaging. *Neuron* **97**, 263-268 (2018).
- 12 10. Tian, Y.E., *et al.* Heterogeneous aging across multiple organ systems and  
13 prediction of chronic disease and mortality. *Nature Medicine*, 1-11 (2023).
- 14 11. Taschler, B., Smith, S.M. & Nichols, T.E. Causal inference on neuroimaging data  
15 with Mendelian randomisation. *NeuroImage*, 119385 (2022).
- 16 12. Sanderson, E., *et al.* Mendelian randomization. *Nature Reviews Methods Primers*  
17 **2**, 1-21 (2022).
- 18 13. Pingault, J.-B., *et al.* Using genetic data to strengthen causal inference in  
19 observational research. *Nature Reviews Genetics* **19**, 566-580 (2018).
- 20 14. Aung, N., *et al.* Genome-wide analysis of left ventricular image-derived  
21 phenotypes identifies fourteen loci associated with cardiac morphogenesis and  
22 heart failure development. *Circulation* **140**, 1318-1330 (2019).
- 23 15. Córdova-Palomera, A., *et al.* Cardiac Imaging of Aortic Valve Area From 34 287  
24 UK Biobank Participants Reveals Novel Genetic Associations and Shared Genetic  
25 Comorbidity With Multiple Disease Phenotypes. *Circulation: Genomic and*  
26 *Precision Medicine* **13**, e003014 (2020).
- 27 16. Meyer, H.V., *et al.* Genetic and functional insights into the fractal structure of the  
28 heart. *Nature* **584**, 589-594 (2020).
- 29 17. Pirruccello, J.P., *et al.* Analysis of cardiac magnetic resonance imaging in 36,000  
30 individuals yields genetic insights into dilated cardiomyopathy. *Nature*  
31 *communications* **11**, 1-10 (2020).

- 1 18. Pirruccello, J.P., *et al.* Genetic Analysis of Right Heart Structure and Function in  
2 40,000 People. *bioRxiv* (2021).
- 3 19. Thanaj, M., *et al.* Genetic and environmental determinants of diastolic heart  
4 function. *medRxiv* (2021).
- 5 20. Elliott, L.T., *et al.* Genome-wide association studies of brain imaging phenotypes  
6 in UK Biobank. *Nature* **562**, 210-216 (2018).
- 7 21. Zhao, B., *et al.* Genome-wide association analysis of 19,629 individuals identifies  
8 variants influencing regional brain volumes and refines their genetic co-  
9 architecture with cognitive and mental health traits. *Nature genetics* **51**, 1637-  
10 1644 (2019).
- 11 22. Smith, S.M., *et al.* An expanded set of genome-wide association studies of brain  
12 imaging phenotypes in UK Biobank. *Nature neuroscience* **24**, 737-745 (2021).
- 13 23. Zhao, B., *et al.* Common genetic variation influencing human white matter  
14 microstructure. *Science* **372**, eabf3736 (2021).
- 15 24. Grasby, K.L., *et al.* The genetic architecture of the human cerebral cortex. *Science*  
16 **367**, eaay6690 (2020).
- 17 25. Zhao, B., *et al.* Genetic influences on the intrinsic and extrinsic functional  
18 organizations of the cerebral cortex. *medRxiv*, 2021.2007. 2027.21261187  
19 (2021).
- 20 26. Watanabe, K., *et al.* A global overview of pleiotropy and genetic architecture in  
21 complex traits. *Nature genetics* **51**, 1339-1348 (2019).
- 22 27. Kurki, M.I., *et al.* FinnGen: Unique genetic insights from combining isolated  
23 population and national health register data. *medRxiv* (2022).
- 24 28. Flynn, B.I., *et al.* Deep learning based phenotyping of medical images improves  
25 power for gene discovery of complex disease. *medRxiv*, 2023.2003.  
26 2007.23286909 (2023).
- 27 29. Kun, E., *et al.* The genetic architecture of the human skeletal form. *bioRxiv*  
28 (2023).
- 29 30. Guo, J., *et al.* Mendelian randomization analyses support causal relationships  
30 between brain imaging-derived phenotypes and risk of psychiatric disorders.  
31 *Nature Neuroscience* **25**, 1519-1527 (2022).

- 1 31. Chen, X., *et al.* Kidney damage causally affects the brain cortical structure: a  
2 Mendelian randomization study. *EBioMedicine* **72**, 103592 (2021).
- 3 32. Williams, J.A., *et al.* Inflammation and brain structure in schizophrenia and other  
4 neuropsychiatric disorders: a Mendelian randomization study. *JAMA psychiatry*  
5 **79**, 498-507 (2022).
- 6 33. Topiwala, A., *et al.* Associations between moderate alcohol consumption, brain  
7 iron, and cognition in UK Biobank participants: observational and mendelian  
8 randomization analyses. *PLoS medicine* **19**, e1004039 (2022).
- 9 34. Holmes, M.V., *et al.* Mendelian randomization of blood lipids for coronary heart  
10 disease. *European heart journal* **36**, 539-550 (2015).
- 11 35. Lamina, C. & Kronenberg, F. Estimation of the required lipoprotein (a)-lowering  
12 therapeutic effect size for reduction in coronary heart disease outcomes: a  
13 Mendelian randomization analysis. *JAMA cardiology* **4**, 575-579 (2019).
- 14 36. Sudlow, C., *et al.* UK biobank: an open access resource for identifying the causes  
15 of a wide range of complex diseases of middle and old age. *PLoS medicine* **12**,  
16 e1001779 (2015).
- 17 37. Bijsterbosch, J., *et al.* Investigations into within-and between-subject resting-  
18 state amplitude variations. *Neuroimage* **159**, 57-69 (2017).
- 19 38. Bai, W., *et al.* A population-based phenome-wide association study of cardiac  
20 and aortic structure and function. *Nature Medicine* **26**, 1654-1662 (2020).
- 21 39. Zhao, B., *et al.* Heart-brain connections: phenotypic and genetic insights from  
22 magnetic resonance images. *Science*, just-accepted (2023).
- 23 40. Bowden, J., *et al.* A framework for the investigation of pleiotropy in two-sample  
24 summary data Mendelian randomization. *Statistics in medicine* **36**, 1783-1802  
25 (2017).
- 26 41. Burgess, S., Butterworth, A. & Thompson, S.G. Mendelian randomization analysis  
27 with multiple genetic variants using summarized data. *Genetic epidemiology* **37**,  
28 658-665 (2013).
- 29 42. Bowden, J., *et al.* Improving the accuracy of two-sample summary-data  
30 Mendelian randomization: moving beyond the NOME assumption. *Int J*  
31 *Epidemiol* **48**, 728-742 (2019).

- 1 43. Bowden, J., Davey Smith, G. & Burgess, S. Mendelian randomization with invalid  
2 instruments: effect estimation and bias detection through Egger regression.  
3 *International journal of epidemiology* **44**, 512-525 (2015).
- 4 44. Hartwig, F.P., Davey Smith, G. & Bowden, J. Robust inference in summary data  
5 Mendelian randomization via the zero modal pleiotropy assumption.  
6 *International journal of epidemiology* **46**, 1985-1998 (2017).
- 7 45. Bowden, J., Davey Smith, G., Haycock, P.C. & Burgess, S. Consistent estimation in  
8 Mendelian randomization with some invalid instruments using a weighted  
9 median estimator. *Genetic epidemiology* **40**, 304-314 (2016).
- 10 46. Ye, T., Shao, J. & Kang, H. Debiased inverse-variance weighted estimator in two-  
11 sample summary-data Mendelian randomization. *The Annals of statistics* **49**,  
12 2079-2100 (2021).
- 13 47. Zhao, Q., Wang, J., Hemani, G., Bowden, J. & Small, D.S. Statistical inference in  
14 two-sample summary-data Mendelian randomization using robust adjusted  
15 profile score. *The Annals of Statistics* **48**, 1742-1769 (2020).
- 16 48. Wang, J., *et al.* Causal inference for heritable phenotypic risk factors using  
17 heterogeneous genetic instruments. *PLoS genetics* **17**, e1009575 (2021).
- 18 49. Oishi, K., Mielke, M.M., Albert, M., Lyketsos, C.G. & Mori, S. DTI analyses and  
19 clinical applications in Alzheimer's disease. *J Alzheimers Dis* **26 Suppl 3**, 287-296  
20 (2011).
- 21 50. Yin, R.-H., *et al.* Multimodal voxel-based meta-analysis of white matter  
22 abnormalities in Alzheimer's disease. *Journal of Alzheimer's Disease* **47**, 495-507  
23 (2015).
- 24 51. Li, R., *et al.* Attention-related networks in Alzheimer's disease: A resting  
25 functional MRI study. *Human brain mapping* **33**, 1076-1088 (2012).
- 26 52. Stratos, C., Stefanadis, C., Kallikazaros, I., Boudoulas, H. & Toutouzas, P.  
27 Ascending aorta distensibility abnormalities in hypertensive patients and  
28 response to nifedipine administration. *The American journal of medicine* **93**, 505-  
29 512 (1992).
- 30 53. Asmar, R., *et al.* Aortic distensibility in normotensive, untreated and treated  
31 hypertensive patients. *Blood pressure* **4**, 48-54 (1995).

- 1 54. Nabati, M., Namazi, S.S., Yazdani, J. & Sharif Nia, H. Relation between aortic  
2 stiffness index and distensibility with age in hypertensive patients. *International*  
3 *journal of general medicine*, 297-303 (2020).
- 4 55. Lembo, M., *et al.* Advanced imaging tools for evaluating cardiac morphological  
5 and functional impairment in hypertensive disease. *Journal of Hypertension* **40**,  
6 4-14 (2022).
- 7 56. Di Palo, K.E. & Barone, N.J. Hypertension and heart failure: prevention, targets,  
8 and treatment. *Heart failure clinics* **16**, 99-106 (2020).
- 9 57. Gopinathannair, R., *et al.* Managing atrial fibrillation in patients with heart failure  
10 and reduced ejection fraction: a scientific statement from the American Heart  
11 Association. *Circulation: Arrhythmia and Electrophysiology* **14**, e000078 (2021).
- 12 58. Packer, M. Do most patients with obesity or type 2 diabetes, and atrial  
13 fibrillation, also have undiagnosed heart failure? A critical conceptual framework  
14 for understanding mechanisms and improving diagnosis and treatment.  
15 *European journal of heart failure* **22**, 214-227 (2020).
- 16 59. Fujikura, K., *et al.* Aortic enlargement in chronic obstructive pulmonary disease  
17 (COPD) and emphysema: The Multi-Ethnic Study of Atherosclerosis (MESA) COPD  
18 study. *Int J Cardiol* **331**, 214-220 (2021).
- 19 60. Maclay, J.D., *et al.* Systemic elastin degradation in chronic obstructive pulmonary  
20 disease. *Thorax* **67**, 606-612 (2012).
- 21 61. Berman, M.N., Tupper, C. & Bhardwaj, A. Physiology, Left Ventricular Function.  
22 (2019).
- 23 62. Kim, D.-Y. & Camilleri, M. Serotonin: a mediator of the brain–gut connection.  
24 *Official journal of the American College of Gastroenterology| ACG* **95**, 2698-2709  
25 (2000).
- 26 63. Jones, M., Dilley, J., Drossman, D. & Crowell, M. Brain–gut connections in  
27 functional GI disorders: anatomic and physiologic relationships.  
28 *Neurogastroenterology & Motility* **18**, 91-103 (2006).
- 29 64. Keefer, L., *et al.* A Rome working team report on brain-gut behavior therapies for  
30 disorders of gut-brain interaction. *Gastroenterology* **162**, 300-315 (2022).
- 31 65. Xie, Z., Tong, S., Chu, X., Feng, T. & Geng, M. Chronic kidney disease and  
32 cognitive impairment: The kidney-brain axis. *Kidney Diseases* **8**, 275-285 (2022).



- 1 66. de Donato, A., Buonincontri, V., Borriello, G., Martinelli, G. & Mone, P. The  
2 dopamine system: insights between kidney and brain. *Kidney and Blood Pressure*  
3 *Research* **47**, 493-505 (2022).
- 4 67. McCracken, C., *et al.* Multi-organ imaging demonstrates the heart-brain-liver axis  
5 in UK Biobank participants. *Nature Communications* **13**, 7839 (2022).
- 6 68. Voulgaris, A., Marrone, O., Bonsignore, M.R. & Steiropoulos, P. Chronic kidney  
7 disease in patients with obstructive sleep apnea. A narrative review. *Sleep*  
8 *Medicine Reviews* **47**, 74-89 (2019).
- 9 69. Sim, J.J., Rasgon, S.A. & Derosé, S.F. Managing sleep apnoea in kidney diseases.  
10 *Nephrology* **15**, 146-152 (2010).
- 11 70. O'Reilly, R.A. Splenomegaly in 2,505 patients in a large university medical center  
12 from 1913 to 1995. 1913 to 1962: 2,056 patients. *Western journal of medicine*  
13 **169**, 78 (1998).
- 14 71. Vinchi, F., *et al.* Atherosclerosis is aggravated by iron overload and ameliorated  
15 by dietary and pharmacological iron restriction. *European heart journal* **41**, 2681-  
16 2695 (2020).
- 17 72. Kempf, T. & Wollert, K.C. Iron and atherosclerosis: too much of a good thing can  
18 be bad. *European Heart Journal* (2020).
- 19 73. Balint, G.P. & Balint, P.V. Felty's syndrome. *Best practice & research clinical*  
20 *rheumatology* **18**, 631-645 (2004).
- 21 74. Blendis, L., Ansell, I., Jones, K.L., Hamilton, E. & Williams, R. Liver in Felty's  
22 syndrome. *Br Med J* **1**, 131-135 (1970).
- 23 75. Kataria, Y.P. & Whitcomb, M.E. Splenomegaly in sarcoidosis. *Archives of Internal*  
24 *Medicine* **140**, 35-37 (1980).
- 25 76. Candia, L., Marquez, J. & Espinoza, L.R. Autoimmune hepatitis and pregnancy: a  
26 rheumatologist's dilemma. in *Seminars in arthritis and rheumatism*, Vol. 35 49-56  
27 (Elsevier, 2005).
- 28 77. Wang, Z., *et al.* Iron drives T helper cell pathogenicity by promoting RNA-binding  
29 protein PCBP1-mediated proinflammatory cytokine production. *Immunity* **49**, 80-  
30 92. e87 (2018).
- 31 78. Erie, J.C., *et al.* Heavy metal concentrations in human eyes. *American journal of*  
32 *ophthalmology* **139**, 888-893 (2005).

- 1 79. Honka, H., *et al.* The effects of bariatric surgery on pancreatic lipid metabolism  
2 and blood flow. *The Journal of Clinical Endocrinology & Metabolism* **100**, 2015-  
3 2023 (2015).
- 4 80. Huang, J.-A., Lin, C.-H., Chang, Y.-T., Lee, C.-T. & Wu, M.-J. Nephrotic syndrome is  
5 associated with increased risk of ischemic stroke. *Journal of Stroke and*  
6 *Cerebrovascular Diseases* **28**, 104322 (2019).
- 7 81. Gigante, A., *et al.* Nephrotic syndrome and stroke. *International Journal of*  
8 *Immunopathology and Pharmacology* **26**, 769-772 (2013).
- 9 82. Roy, C., *et al.* Ischemic stroke of possible embolic etiology associated with  
10 nephrotic syndrome. *Kidney International Reports* **2**, 988-994 (2017).
- 11 83. Cheon, S.Y. & Song, J. Novel insights into non-alcoholic fatty liver disease and  
12 dementia: insulin resistance, hyperammonemia, gut dysbiosis, vascular  
13 impairment, and inflammation. *Cell & Bioscience* **12**, 1-14 (2022).
- 14 84. Rodrigo, R., *et al.* Hyperammonemia induces neuroinflammation that  
15 contributes to cognitive impairment in rats with hepatic encephalopathy.  
16 *Gastroenterology* **139**, 675-684 (2010).
- 17 85. Rose, C.F., *et al.* Hepatic encephalopathy: Novel insights into classification,  
18 pathophysiology and therapy. *Journal of hepatology* **73**, 1526-1547 (2020).
- 19 86. Kong, S.H., Park, Y.J., Lee, J.-Y., Cho, N.H. & Moon, M.K. Insulin resistance is  
20 associated with cognitive decline among older Koreans with normal baseline  
21 cognitive function: a prospective community-based cohort study. *Scientific*  
22 *reports* **8**, 650 (2018).
- 23 87. Hobson-Webb, L.D., Massey, J.M., Juel, V.C. & Sanders, D.B. The  
24 ultrasonographic wrist-to-forearm median nerve area ratio in carpal tunnel  
25 syndrome. *Clinical neurophysiology* **119**, 1353-1357 (2008).
- 26 88. Paluch, Ł., Pietruski, P., Walecki, J. & Noszczyk, B.H. Wrist to forearm ratio as a  
27 median nerve shear wave elastography test in carpal tunnel syndrome diagnosis.  
28 *Journal of Plastic, Reconstructive & Aesthetic Surgery* **71**, 1146-1152 (2018).
- 29 89. Gotsopoulos, H., Chen, C., Qian, J. & Cistulli, P.A. Oral appliance therapy  
30 improves symptoms in obstructive sleep apnea: a randomized, controlled trial.  
31 *American journal of respiratory and critical care medicine* **166**, 743-748 (2002).

- 1 90. Araie, T., Okuno, K., Minagi, H.O. & Sakai, T. Dental and skeletal changes  
2 associated with long-term oral appliance use for obstructive sleep apnea: a  
3 systematic review and meta-analysis. *Sleep Medicine Reviews* **41**, 161-172  
4 (2018).
- 5 91. Sander, J.E. & Sharp, F.R. Lumbosacral plexus neuritis. *Neurology* **31**, 470-473  
6 (1981).
- 7 92. Khamis, S. & Carmeli, E. A new concept for measuring leg length discrepancy.  
8 *Journal of orthopaedics* **14**, 276-280 (2017).
- 9 93. Raczkowski, J.W., Daniszewska, B. & Zolynski, K. Functional scoliosis caused by  
10 leg length discrepancy. *Archives of Medical Science* **6**, 393-398 (2010).
- 11 94. Nelson, C.P., *et al.* Genetically determined height and coronary artery disease.  
12 *New England Journal of Medicine* **372**, 1608-1618 (2015).
- 13 95. Schmidt, M., Bøtker, H.E., Pedersen, L. & Sørensen, H.T. Adult height and risk of  
14 ischemic heart disease, atrial fibrillation, stroke, venous thromboembolism, and  
15 premature death: a population based 36-year follow-up study. *European journal*  
16 *of epidemiology* **29**, 111-118 (2014).
- 17 96. Yin, F., Spurgeon, H.A., Rakusan, K., Weisfeldt, M.L. & Lakatta, E.G. Use of tibial  
18 length to quantify cardiac hypertrophy: application in the aging rat. *American*  
19 *Journal of Physiology-Heart and Circulatory Physiology* **243**, H941-H947 (1982).
- 20 97. Walker, V.M., Zheng, J., Gaunt, T.R. & Smith, G.D. Phenotypic Causal Inference  
21 Using Genome-Wide Association Study Data: Mendelian Randomization and  
22 Beyond. *Annu Rev Biomed Data Sci* **5**, 1-17 (2022).
- 23 98. Burgess, S., Davies, N.M. & Thompson, S.G. Bias due to participant overlap in  
24 two-sample Mendelian randomization. *Genetic epidemiology* **40**, 597-608 (2016).
- 25 99. Berridge, K.C. & Kringelbach, M.L. Pleasure systems in the brain. *Neuron* **86**, 646-  
26 664 (2015).
- 27 100. Bressler, S.L. & Menon, V. Large-scale brain networks in cognition: emerging  
28 methods and principles. *Trends Cogn Sci* **14**, 277-290 (2010).
- 29 101. Wang, K., *et al.* Altered functional connectivity in early Alzheimer's disease: A  
30 resting-state fMRI study. *Human brain mapping* **28**, 967-978 (2007).

- 1 102. Sorg, C., *et al.* Selective changes of resting-state networks in individuals at risk  
2 for Alzheimer's disease. *Proceedings of the National Academy of Sciences* **104**,  
3 18760-18765 (2007).
- 4 103. Ranasinghe, K.G., *et al.* Regional functional connectivity predicts distinct  
5 cognitive impairments in Alzheimer's disease spectrum. *NeuroImage: Clinical* **5**,  
6 385-395 (2014).
- 7 104. Pini, L., *et al.* A low-dimensional cognitive-network space in Alzheimer's disease  
8 and frontotemporal dementia. *Alzheimer's Research & Therapy* **14**, 199 (2022).
- 9 105. Liu, W., *et al.* Brain–heart communication in health and diseases. *Brain Research*  
10 *Bulletin* (2022).
- 11 106. Walker, K.A., Power, M.C. & Gottesman, R.F. Defining the relationship between  
12 hypertension, cognitive decline, and dementia: a review. *Current hypertension*  
13 *reports* **19**, 1-16 (2017).
- 14 107. Zhang, H., *et al.* Reduced regional gray matter volume in patients with chronic  
15 obstructive pulmonary disease: a voxel-based morphometry study. *American*  
16 *Journal of Neuroradiology* **34**, 334-339 (2013).
- 17 108. do Carmo, J.M., *et al.* Role of the brain melanocortins in blood pressure  
18 regulation. *Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease* **1863**,  
19 2508-2514 (2017).
- 20 109. Goriely, A., *et al.* Mechanics of the brain: perspectives, challenges, and  
21 opportunities. *Biomechanics and modeling in mechanobiology* **14**, 931-965  
22 (2015).
- 23 110. Polkey, M.I., Lyall, R.A., Moxham, J. & Leigh, P.N. Respiratory aspects of  
24 neurological disease. *Journal of Neurology, Neurosurgery & Psychiatry* **66**, 5-15  
25 (1999).
- 26 111. Pollock, R.D., Rafferty, G.F., Moxham, J. & Kalra, L. Respiratory muscle strength  
27 and training in stroke and neurology: a systematic review. *International Journal*  
28 *of Stroke* **8**, 124-130 (2013).
- 29 112. Tian, C., Zhao, J., Xiong, Q., Yu, H. & Du, H. Secondary iron overload induces  
30 chronic pancreatitis and ferroptosis of acinar cells in mice. *International Journal*  
31 *of Molecular Medicine* **51**, 1-13 (2023).

- 1 113. Galaris, D., Barbouti, A. & Pantopoulos, K. Iron homeostasis and oxidative stress:  
2 An intimate relationship. *Biochimica et Biophysica Acta (BBA)-Molecular Cell*  
3 *Research* **1866**, 118535 (2019).
- 4 114. Robles, L., Vaziri, N.D. & Ichii, H. Role of oxidative stress in the pathogenesis of  
5 pancreatitis: effect of antioxidant therapy. *Pancreatic disorders & therapy* **3**, 112  
6 (2013).
- 7 115. Armstrong, J., *et al.* Oxidative stress in acute pancreatitis: lost in translation?  
8 *Free radical research* **47**, 917-933 (2013).
- 9 116. Pérez, S., Pereda, J., Sabater, L. & Sastre, J. Redox signaling in acute pancreatitis.  
10 *Redox biology* **5**, 1-14 (2015).
- 11 117. Kushner, T. & Cafardi, J. Chronic liver disease and COVID-19: alcohol use  
12 disorder/alcohol-associated liver disease, nonalcoholic fatty liver  
13 disease/nonalcoholic steatohepatitis, autoimmune liver disease, and  
14 compensated cirrhosis. *Clinical Liver Disease* **15**, 195 (2020).
- 15 118. Grant, I., Heaton, R.K., McSweeney, A.J., Adams, K.M. & Timms, R.M. Brain  
16 dysfunction in COPD. *Chest* **77**, 308-309 (1980).
- 17 119. Spilling, C.A., *et al.* Factors affecting brain structure in smoking-related diseases:  
18 Chronic Obstructive Pulmonary Disease (COPD) and coronary artery disease.  
19 *PLoS One* **16**, e0259375 (2021).
- 20 120. Kim, G.A., *et al.* Association between non-alcoholic fatty liver disease and the risk  
21 of dementia: a nationwide cohort study. *Liver international* **42**, 1027-1036  
22 (2022).
- 23 121. Kim, D.-G., *et al.* Non-alcoholic fatty liver disease induces signs of Alzheimer's  
24 disease (AD) in wild-type mice and accelerates pathological signs of AD in an AD  
25 model. *Journal of neuroinflammation* **13**, 1-18 (2016).
- 26 122. Wang, L., Sang, B. & Zheng, Z. Risk of dementia or cognitive impairment in non-  
27 alcoholic fatty liver disease: A systematic review and meta-analysis. *Frontiers in*  
28 *Aging Neuroscience* **14**(2022).
- 29 123. Mobeen, S. & Apostol, R. Ovarian cyst. (2020).
- 30 124. Padda, J., *et al.* Depression and its effect on the menstrual cycle. *Cureus*  
31 **13**(2021).

- 1 125. Azari, A.A. & Barney, N.P. Conjunctivitis: a systematic review of diagnosis and  
2 treatment. *Jama* **310**, 1721-1730 (2013).
- 3 126. Sankowski, R., Mader, S. & Valdés-Ferrer, S.I. Systemic inflammation and the  
4 brain: novel roles of genetic, molecular, and environmental cues as drivers of  
5 neurodegeneration. *Frontiers in cellular neuroscience* **9**, 28 (2015).
- 6 127. Elwood, E., Lim, Z., Naveed, H. & Galea, I. The effect of systemic inflammation on  
7 human brain barrier function. *Brain, behavior, and immunity* **62**, 35-40 (2017).
- 8 128. Rhyou, H.-I. & Nam, Y.-H. Association between cognitive function and asthma in  
9 adults. *Annals of Allergy, Asthma & Immunology* **126**, 69-74 (2021).
- 10 129. Ray, M., Sano, M., Wisnivesky, J.P., Wolf, M.S. & Federman, A.D. Asthma control  
11 and cognitive function in a cohort of elderly adults. *Journal of the American*  
12 *Geriatrics Society* **63**, 684-691 (2015).
- 13 130. Alvarez, J.I., Cayrol, R. & Prat, A. Disruption of central nervous system barriers in  
14 multiple sclerosis. *Biochimica et Biophysica Acta (BBA)-Molecular Basis of*  
15 *Disease* **1812**, 252-264 (2011).
- 16 131. Krupp, L.B., *et al.* International Pediatric Multiple Sclerosis Study Group criteria  
17 for pediatric multiple sclerosis and immune-mediated central nervous system  
18 demyelinating disorders: revisions to the 2007 definitions. *Multiple Sclerosis*  
19 *Journal* **19**, 1261-1267 (2013).
- 20 132. Huda, S., *et al.* Neuromyelitis optica spectrum disorders. *Clinical Medicine* **19**,  
21 169 (2019).
- 22 133. Kim, W., Kim, S.-H., Huh, S.-Y. & Kim, H.J. Brain abnormalities in neuromyelitis  
23 optica spectrum disorder. *Multiple sclerosis international* **2012**(2012).
- 24 134. Lancaster, E. The diagnosis and treatment of autoimmune encephalitis. *Journal*  
25 *of Clinical Neurology* **12**, 1-13 (2016).
- 26 135. Wartolowska, K., *et al.* Structural changes of the brain in rheumatoid arthritis.  
27 *Arthritis & Rheumatism* **64**, 371-379 (2012).
- 28 136. Kozora, E. & Filley, C.M. Cognitive dysfunction and white matter abnormalities in  
29 systemic lupus erythematosus. *Journal of the International Neuropsychological*  
30 *Society* **17**, 385-392 (2011).
- 31 137. Appenzeller, S., *et al.* Longitudinal analysis of gray and white matter loss in  
32 patients with systemic lupus erythematosus. *Neuroimage* **34**, 694-701 (2007).

- 1 138. Rosenberg, G.A. Inflammation and white matter damage in vascular cognitive  
2 impairment. *Stroke* **40**, S20-S23 (2009).
- 3 139. Raj, D., *et al.* Increased white matter inflammation in aging-and Alzheimer's  
4 disease brain. *Frontiers in molecular neuroscience* **10**, 206 (2017).
- 5 140. Gerds, E., *et al.* Correlates of left atrial size in hypertensive patients with left  
6 ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in  
7 Hypertension (LIFE) Study. *Hypertension* **39**, 739-743 (2002).
- 8 141. Eshoo, S., Ross, D.L. & Thomas, L. Impact of mild hypertension on left atrial size  
9 and function. *Circulation: Cardiovascular Imaging* **2**, 93-99 (2009).
- 10 142. Sanfilippo, A.J., *et al.* Atrial enlargement as a consequence of atrial fibrillation. A  
11 prospective echocardiographic study. *Circulation* **82**, 792-797 (1990).
- 12 143. van de Vegte, Y.J., Siland, J.E., Rienstra, M. & van der Harst, P. Atrial fibrillation  
13 and left atrial size and function: a Mendelian randomization study. *Scientific*  
14 *reports* **11**, 8431 (2021).
- 15 144. Hiraiwa, H., *et al.* Clinical significance of spleen size in patients with heart failure.  
16 *European Heart Journal* **42**, ehab724. 0756 (2021).
- 17 145. Ormazabal, V., *et al.* Association between insulin resistance and the  
18 development of cardiovascular disease. *Cardiovascular diabetology* **17**, 1-14  
19 (2018).
- 20 146. Shah, A., Mehta, N. & Reilly, M.P. Adipose inflammation, insulin resistance, and  
21 cardiovascular disease. *Journal of Parenteral and Enteral Nutrition* **32**, 638-644  
22 (2008).
- 23 147. Thurlbeck, W.M. & Müller, N. Emphysema: definition, imaging, and  
24 quantification. *AJR. American journal of roentgenology* **163**, 1017-1025 (1994).
- 25 148. Fernández-García, V., González-Ramos, S., Martín-Sanz, P., Castrillo, A. & Boscá,  
26 L. Contribution of extramedullary hematopoiesis to atherosclerosis. The spleen  
27 as a neglected hub of inflammatory cells. *Frontiers in Immunology* **11**, 586527  
28 (2020).
- 29 149. Suttorp, M. & Classen, C.F. Splenomegaly in children and adolescents. *Frontiers*  
30 *in pediatrics*, 693 (2021).
- 31 150. Lampropoulos, C.E., Papaioannou, I. & D'cruz, D.P. Osteoporosis—a risk factor  
32 for cardiovascular disease? *Nature Reviews Rheumatology* **8**, 587-598 (2012).

- 1 151. Gaines, J.M., *et al.* Older men's knowledge of osteoporosis and the prevalence of  
2 risk factors. *Journal of Clinical Densitometry* **13**, 204-209 (2010).
- 3 152. Whalen, R., Carter, D. & Steele, C. Influence of physical activity on the regulation  
4 of bone density. *Journal of biomechanics* **21**, 825-837 (1988).
- 5 153. Zhao, Q., Wang, J., Spiller, W., Bowden, J. & Small, D.S. Two-sample instrumental  
6 variable analyses using heterogeneous samples. *Statistical Science* **34**, 317-333  
7 (2019).
- 8 154. Cui, R., *et al.* Improving fine-mapping by modeling infinitesimal effects. *bioRxiv*,  
9 2022.2010. 2021.513123 (2022).
- 10 155. Xue, H., Shen, X. & Pan, W. Causal Inference in Transcriptome-Wide Association  
11 Studies with Invalid Instruments and GWAS Summary Data. *Journal of the*  
12 *American Statistical Association*, 1-27 (2023).
- 13 156. Tseng, W.Y., Su, M.Y. & Tseng, Y.H. Introduction to Cardiovascular Magnetic  
14 Resonance: Technical Principles and Clinical Applications. *Acta Cardiol Sin* **32**,  
15 129-144 (2016).
- 16 157. Pennell, D.J. Cardiovascular magnetic resonance. *Circulation* **121**, 692-705  
17 (2010).
- 18 158. Bai, W., *et al.* Automated cardiovascular magnetic resonance image analysis with  
19 fully convolutional networks. *Journal of Cardiovascular Magnetic Resonance* **20**,  
20 1-12 (2018).
- 21 159. Bai, W., *et al.* Recurrent neural networks for aortic image sequence  
22 segmentation with sparse annotations. *International conference on medical*  
23 *image computing and computer-assisted intervention*, 586-594 (2018).
- 24 160. Miller, K.L., *et al.* Multimodal population brain imaging in the UK Biobank  
25 prospective epidemiological study. *Nat Neurosci* **19**, 1523-1536 (2016).
- 26 161. Zhao, B., *et al.* Heritability of regional brain volumes in large-scale neuroimaging  
27 and genetic studies. *Cerebral Cortex* **29**, 2904-2914 (2019).
- 28 162. Zhao, B., *et al.* Large-scale GWAS reveals genetic architecture of brain white  
29 matter microstructure and genetic overlap with cognitive and mental health  
30 traits (n= 17,706). *Molecular psychiatry* **26**, 3943-3955 (2021).
- 31 163. Avants, B.B., *et al.* A reproducible evaluation of ANTs similarity metric  
32 performance in brain image registration. *Neuroimage* **54**, 2033-2044 (2011).



- 1 164. Jahanshad, N., *et al.* Multi-site genetic analysis of diffusion images and voxelwise  
2 heritability analysis: A pilot project of the ENIGMA–DTI working group.  
3 *Neuroimage* **81**, 455-469 (2013).
- 4 165. Kochunov, P., *et al.* Multi-site study of additive genetic effects on fractional  
5 anisotropy of cerebral white matter: comparing meta and megaanalytical  
6 approaches for data pooling. *Neuroimage* **95**, 136-150 (2014).
- 7 166. Glasser, M.F., *et al.* A multi-modal parcellation of human cerebral cortex. *Nature*  
8 **536**, 171-178 (2016).
- 9 167. Ji, J.L., *et al.* Mapping the human brain's cortical-subcortical functional network  
10 organization. *Neuroimage* **185**, 35-57 (2019).
- 11 168. Bowden, J., *et al.* Improving the accuracy of two-sample summary-data  
12 Mendelian randomization: moving beyond the NOME assumption. *International*  
13 *journal of epidemiology* **48**, 728-742 (2019).

14

## 15 **METHODS**

### 16 **Multi-organ imaging biomarkers.**

17 The imaging data were sourced from the UK Biobank (UKB) study, which enrolled  
18 approximately 500,000 individuals aged between 40 and 69 from 2006 to 2010  
19 (<https://www.ukbiobank.ac.uk/>). These multi-organ imaging data were collected from  
20 the ongoing UKB imaging study project ([https://www.ukbiobank.ac.uk/explore-your-  
21 participation/contribute-further/imaging-study](https://www.ukbiobank.ac.uk/explore-your-participation/contribute-further/imaging-study)), which aims to collect brain, heart, and  
22 abdomen scans from 100,000 participants. Ethical approval for the UKB study was  
23 secured from the North West Multicentre Research Ethics Committee (approval number:  
24 11/NW/0382).

25

26 Studies of brain and heart diseases usually rely on magnetic resonance imaging (MRI)  
27 scans, which are well-established clinical endophenotypes. Cardiovascular magnetic  
28 resonance imaging (CMR) is a set of MRI techniques that are designed to assess  
29 ventricular function, cardiovascular morphology, myocardial perfusion, and other cardiac  
30 functional and structural features<sup>156,157</sup>. They have been frequently used to reveal heart-  
31 related issues clinically. The CMR traits used in the paper were originally generated from  
32 the raw short-axis, long-axis, and aortic cine images using the state-of-the-art heart

1 imaging segmentation and feature representation framework<sup>38,158,159</sup>. We divided the  
2 generated 82 CMR traits into 6 categories. The first two are aortic sections, namely  
3 ascending aorta (AAo) and descending aorta (DAo), which serve as the main ‘pipe’ in  
4 supplying blood to the entire body. The other four are the global measures of 4 cardiac  
5 chambers, including the left ventricle (LV), right ventricle (RV), left atrium (LA), and right  
6 atrium (RA), which altogether manage the heartbeat and blood flow. There are also some  
7 other traits, such as regional phenotypes of the left ventricle myocardial-wall thickness  
8 and strain (**Table S1**). The summary-level GWAS data of these 82 CMR traits were  
9 obtained from Zhao, et al.<sup>39</sup>.

10

11 Brain MRI provides detailed information about brain structure and function<sup>160</sup>, such as  
12 abnormal growth, healthy aging, white matter diseases, structural issues, and functional  
13 abnormalities. In this paper, the summary-level GWAS data were collected from recent  
14 multi-modal image genetic studies, including regional brain volumes from structural  
15 MRI<sup>21,161</sup> (sMRI), diffusion tensor imaging (DTI) parameters from diffusion MRI<sup>23,162</sup> (dMRI),  
16 and functional activity (that is, amplitude<sup>37</sup>) and functional connectivity phenotypes from  
17 resting functional MRI<sup>25</sup> (resting fMRI). In sMRI, we used ANTs<sup>163</sup> to generate regional  
18 brain volumes for cortical and subcortical regions and global brain volume measures. In  
19 dMRI, we used the ENIGMA-DTI pipelines<sup>164,165</sup> to generate tract-averaged parameters  
20 for fractional anisotropy, mean diffusivity, axial diffusivity, radial diffusivity, and mode of  
21 anisotropy in major white matter tracts and across the whole brain. For resting fMRI, we  
22 extracted phenotypes from brain parcellation-based analysis. We used the Glasser360  
23 atlas<sup>166</sup>, which divided the cerebral cortex into 360 regions in 12 functional networks<sup>167</sup>.  
24 We considered 90 network-level resting fMRI phenotypes that evaluated interactions and  
25 spontaneous neural activity at rest.

26

27 The 11 imaging biomarkers from abdominal MRI were derived by Liu., et al<sup>8</sup> using deep  
28 learning methods in terms of volume, fat, and iron in several organs and tissues, such as  
29 the liver, spleen, kidney, lung, pancreas, and adipose tissue. Skeleton DXA traits, including  
30 all long bone lengths as well as hip and shoulder width, were derived by Kun., et al<sup>3</sup> using  
31 deep learning methods on whole-body dual-energy X-ray absorptiometry (DXA) images.

1 All eight skeleton traits have been controlled for height. The heritability of the above  
2 imaging biomarkers can be found in **Supplementary Note**.

3

#### 4 **FinnGen clinical endpoints.**

5 We used 88 clinical endpoints collected by the FinnGen project, which were selected from  
6 the R7 release and with more than 10,000 cases for most of the clinical endpoints  
7 ([https://www.finnngen.fi/en/access\\_results](https://www.finnngen.fi/en/access_results)). As for some important diseases, such as  
8 Alzheimer's disease, we set the cutoff of the number of cases to be 6,000. The 88 clinical  
9 endpoints covered diseases from various categories, namely, mental and behavioral  
10 disorders, diseases of the nervous system, diseases of the eye and adnexa, diseases of the  
11 genitourinary system, diseases of the circulatory systems, cardiometabolic endpoints,  
12 diseases marked as autoimmune origin, rheuma endpoints, interstitial lung diseases,  
13 COPD and related endpoints, as well as some unclassified endpoints. The definitions can  
14 be found at <https://risteys.finregistry.fi/>. The FinnGen data used in our study was  
15 obtained from separate cohorts than those supplying imaging traits, which were derived  
16 from the UKB study, thus ensuring there was no sample overlap. Detailed information of  
17 these 88 clinical variables can be found in **Table S2**.

18

#### 19 **Mendelian randomization analysis.**

20 We examined the genetic causal relationships between the 402 imaging traits (101 brain  
21 regional volume traits, 110 brain DTI parameters, 90 network-level fMRI phenotypes, 82  
22 CMR traits, 11 abdominal traits, and 8 skeleton DXA traits) and 88 clinical endpoints. Prior  
23 to conducting the Mendelian randomization (MR) analysis, we conducted standard  
24 preprocessing and quality control procedures. First, we selected genetic variants based  
25 on a significance threshold of  $5 \times 10^{-8}$  in the exposure GWAS data. To ensure the  
26 independence of the genetic variants used in MR, we implemented LD clumping with a  
27 window size of 10,000 and an  $r^2$  threshold of 0.01, using the 1000 Genomes European  
28 ancestry data as a reference panel. We used the TwoSampleMR package  
29 (<https://mrcieu.github.io/TwoSampleMR/>) for harmonization, which enabled us to  
30 accurately align alleles between the selected variants in the exposure and the reported  
31 effect on the outcome.

32

1 We assessed the performance of 8 MR methods, which included Inverse variance  
2 weighted (fixed effect), Inverse variance weighted (multiplicative random effect), MR-  
3 Egger, Simple Median, Weighted Median, Weighted Mode, DIVW, GRAPPLE, and MR-  
4 RAPS<sup>40,41,43-48,168</sup>, where MR Egger was used as the pleiotropy test. To ensure the reliability  
5 of our results, we implemented several quality control procedures. We excluded causal  
6 estimates that relied on fewer than 6 genetic variants, as a larger number of genetic  
7 variants increases the statistical power of MR analysis<sup>46,47</sup>. We retained causal pairs that  
8 were significant in at least two out of the eight methods. We also screened for pleiotropy  
9 by using the MR-Egger intercept, the most used method for testing the pleiotropy  
10 assumption. If a causal estimate failed the MR-Egger intercept test, we required that it  
11 have significant results in at least one of the robust MR methods, such as Weighted  
12 Median, Weighted Model, MR-RAPS, or GRAPPLE. Out of 488 significant findings, 81  
13 causal estimates failed the MR-Egger intercept test. However, when we interpreted the  
14 results, we focused on the ones that passed the MR-Egger intercept test.

15


#### 16 **Code availability**

17 We made use of publicly available software and tools. Our analysis code will be made  
18 freely available at Zenodo.

19


#### 20 **Data availability**

21 We used summary-level GWAS data in this study, which can be obtained from the  
22 FinnGen project ([https://www.finnngen.fi/en/access\\_results](https://www.finnngen.fi/en/access_results)), BIG-KP (<https://bigkp.org/>),  
23 Heart-KP (<https://heartkp.org/>), and project-specific resources detailed in Liu., et al<sup>8</sup> and  
24 Kun., et al<sup>3</sup>. Our multi-organ MR results can be explored at <https://mr4mo.org/>.




1 **Fig. 1 Overview of study design and findings.**

2 **(A).** An overview of our multi-organ imaging genetic study for 88 clinical outcomes. Multi-  
 3 modal brain imaging traits, cardiac imaging traits, abdominal imaging traits, as well as  
 4 skeleton DXA imaging traits were used to investigate the relationship between 88 clinical  
 5 endpoints. We covered a full spectrum of brain imaging modalities, including structural  
 6 MRI, diffusion MRI, and resting fMRI. Cardiac imaging data were composed of short-axis,  
 7 long-axis, and aortic cine images. Volume, iron content, and percent fat were measured  
 8 in 6 different abdominal organs and tissues, resulting in 11 image-derived abdominal  
 9 phenotypes. We have 8 skeleton imaging traits that covered long bone lengths as well as  
 10 hip and shoulder width. **(B).** A high-level summary of our bidirectional findings. IDPs,  
 11 imaging derived phenotypes.




1 **Fig. 2 Selected genetic causal effects of clinical outcomes on brain imaging biomarkers.**  
 2 We illustrated selected significant ( $P < 5.18 \times 10^{-6}$ ) causal genetic links from clinical  
 3 endpoints (Exposure) to brain imaging biomarkers (Outcome) after adjusting for multiple  
 4 testing using the Bonferroni procedure. **(A)**. The causal effect of Alzheimer's disease on  
 5 brain imaging biomarkers. **(B)**. The causal effect of dementia on brain imaging biomarkers.  
 6 **(C)**. The causal effect of hypertension on brain imaging biomarkers. IDP Category,  
 7 category of imaging biomarkers; #IVs, the number of genetic variants used as  
 8 instrumental variables. Different MR methods and their regression coefficients are  
 9 labeled with different colors. See **Table S1** for data resources of clinical endpoints and  
 10 **Table S2** for data resources of imaging biomarkers.



1 **Fig. 3 Selected genetic causal effects of brain imaging biomarkers on clinical endpoints.**  
2 We illustrated selected significant ( $P < 5.18 \times 10^{-6}$ ) causal genetic links from brain imaging  
3 biomarkers (Exposure) to clinical endpoints (Outcome) after adjusting for multiple testing  
4 using the Bonferroni procedure. **(A)**. The causal effect of brain imaging biomarkers on  
5 Alzheimer's diseases. **(B)**. The causal effect of brain imaging biomarkers on dementia. IDP  
6 Category, category of imaging biomarkers; #IVs, the number of genetic variants used as  
7 instrumental variables. Different MR methods and their regression coefficients are  
8 labeled with different colors. See **Table S1** for data resources of clinical endpoints and  
9 **Table S2** for data resources of imaging biomarkers.

10




1 **Fig. 4 Selected genetic causal effects between heart imaging biomarkers and clinical**  
 2 **endpoints.**


3 We illustrated selected significant ( $P < 6.85 \times 10^{-6}$ ) causal genetic links from (A) clinical  
 4 endpoints (Exposure) to heart imaging biomarkers (Outcome) and (B) heart imaging  
 5 biomarkers (Exposure) to clinical endpoints (Outcome) after adjusting for multiple testing  
 6 using the Bonferroni procedure. IDP Category, category of imaging biomarkers; #IVs, the  
 7 number of genetic variants used as instrumental variables. Different MR methods and  
 8 their regression coefficients are labeled with different colors. See **Table S1** for data  
 9 resources of clinical endpoints and **Table S2** for data resources of imaging biomarkers.

10





1 **Fig. 5 Selected genetic causal effects between abdominal imaging biomarkers and**  
 2 **clinical endpoints.**  
 3 We illustrated selected significant ( $P < 6.69 \times 10^{-5}$ ) causal genetic links from (A) clinical  
 4 endpoints (Exposure) to abdominal imaging biomarkers (Outcome) and (B) abdominal  
 5 imaging biomarkers (Exposure) to clinical endpoints (Outcome) after adjusting for  
 6 multiple testing using the Bonferroni procedure. IDP Category, category of imaging  
 7 biomarkers; #IVs, the number of genetic variants used as instrumental variables. Different  
 8 MR methods and their regression coefficients are labeled with different colors. See **Table**  
 9 **S1** for data resources of clinical endpoints and **Table S2** for data resources of imaging  
 10 biomarkers.



1 **Fig. 6 Selected genetic causal effects between skeleton imaging biomarkers and clinical**  
2 **endpoints.**  
3 We illustrated selected significant ( $P < 3.39 \times 10^{-5}$ ) causal genetic links from (A) clinical  
4 endpoints to (Exposure) to skeleton imaging biomarkers (Outcome) and (B) skeleton  
5 imaging biomarkers (Exposure) to clinical endpoints (Outcome) after adjusting for  
6 multiple testing using the Bonferroni procedure. IDP Category, category of imaging  
7 biomarkers; #IVs, the number of genetic variants used as instrumental variables. Different  
8 MR methods and their regression coefficients are labeled with different colors. See **Table**  
9 **S1** for data resources of clinical endpoints and **Table S2** for data resources of imaging  
10 biomarkers.